Mitral regurgitation after anthracycline exposure: a case report Case report
Article Sidebar
Main Article Content
Abstract
We report the case of a 66-year-old African American female with a history of breast cancer previously treated with anthracycline based chemotherapy presenting with significant mitral regurgitation. She initially had preserved left ventricular systolic function with normal cardiac chamber dimensions, however, she developed progressive left ventricular chamber dilation and mild reduction in systolic function, which prompted surgical correction of her mitral regurgitation. After surgical mitral valve repair, she developed overt left ventricular failure with severe systolic dysfunction; however, she responded well to subsequent medical therapy.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266(12): 1672-7.
3. Allen J, Thomson JD, Lewis IJ, Gibbs Il. Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart 2001; 85(4): 430-2.
4. Friedberg MK, Solt I, Weyl-Ben-Arush M et al. Cardiac function in long-term survivors of childhood lymphoma. Cardiol Res Pract 2011; 2011: 316927.
5. Toro-Salazar OH, Gillan E, O’Loughlin MT et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6(6): 873-80.
6. Kalra K, Wang Q, McIver BV et al. Temporal changes in interpapillary muscle dynamics as an active indicator of mitral valve and left ventricular interaction in ischemic mitral regurgitation. J Am Coll Cardiol 2014; 64(18): 1867-79.
7. Göldel N, Autenrieth G, Werdan K et al. [Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy]. Z Kardiol 1989; 78(5): 320-7.
8. Silber JH. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatr Blood Cancer 2005; 44(7): 607-13.
9. Guimaraes-Filho F, Tan D, Braga J et al. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines. Am J Cardiol 2007; 100(8): 1303-6.
10. Murakami T, Nakazawa M, Nakanishi T, Momma K. End-systolic wall stress is a major determinant of postoperative left ventricular dysfunction in patients with congenital mitral regurgitation. Cardiol Young 2002; 12(3): 236-9.
11. Enriquez-Sarano M, Schaff HV, Orszulak TA et al. Congestive heart failure after surgical correction of mitral regurgitation. A long-term study. Circulation 1995; 92(9): 2496-503.
12. Enriquez-Sarano M, Tajik AJ, Schaff HV et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994; 24(6): 1536-43.
13. Leung DY, Griffin BP, Stewart WJ et al. Left ventricular function after valve repair for chronic mitral regurgitation: predictive value of preoperative assessment of contractile reserve by exercise echocardiography. J Am Coll Cardiol 1996; 28(5): 1198-205.
14. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer, 2013; 49(13): 2900-9.